GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2008

Wuhan Institute of Biological Products to Implement Prometic’s Plasma Fractionation Platform in China

  • Wuhan Institute of Biological Products obtained exclusive access to ProMetic Life Sciences’ Plasma Protein Purification System (PPPS) for the Chinese market.

    Full-scale commercial manufacturing will initially take place at WIBP and could be later implemented by an affiliated firm within China National Biotec Group, WIBP’s parent company. The goal is to achieve a minimum capacity greater than 1.2 million liters of plasma per year.

    ProMetic will assist WIBP in implementing a product development program begining immediately. This includes training, technology transfer, and scale-up as well as readiness of the clinical manufacturing facility. WIBP will take the lead in conducting the clinical trials to obtain required regulatory approval by the Chinese State Food and Drug Administration (SFDA).


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »